GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avid Bioservices Inc (NAS:CDMO) » Definitions » Return-on-Tangible-Equity
中文

Avid Bioservices (Avid Bioservices) Return-on-Tangible-Equity

: -20.33% (As of Oct. 2023)
View and export this data going back to 1996. Start your Free Trial

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Avid Bioservices's annualized net income for the quarter that ended in Oct. 2023 was $-38.0 Mil. Avid Bioservices's average shareholder tangible equity for the quarter that ended in Oct. 2023 was $187.1 Mil. Therefore, Avid Bioservices's annualized Return-on-Tangible-Equity for the quarter that ended in Oct. 2023 was -20.33%.

The historical rank and industry rank for Avid Bioservices's Return-on-Tangible-Equity or its related term are showing as below:

CDMO' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -102.01   Med: -30.98   Max: 101.22
Current: -6.15

During the past 13 years, Avid Bioservices's highest Return-on-Tangible-Equity was 101.22%. The lowest was -102.01%. And the median was -30.98%.

CDMO's Return-on-Tangible-Equity is ranked better than
76.53% of 1308 companies
in the Biotechnology industry
Industry Median: -47.995 vs CDMO: -6.15

Avid Bioservices Return-on-Tangible-Equity Historical Data

The historical data trend for Avid Bioservices's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avid Bioservices Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.75 -22.04 18.74 101.22 0.31

Avid Bioservices Quarterly Data
Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.57 1.01 -0.66 -4.41 -20.33

Competitive Comparison

For the Biotechnology subindustry, Avid Bioservices's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avid Bioservices Return-on-Tangible-Equity Distribution

For the Biotechnology industry and Healthcare sector, Avid Bioservices's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Avid Bioservices's Return-on-Tangible-Equity falls into.



Avid Bioservices Return-on-Tangible-Equity Calculation

Avid Bioservices's annualized Return-on-Tangible-Equity for the fiscal year that ended in Apr. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Apr. 2023 )  (A: Apr. 2022 )(A: Apr. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Apr. 2023 )  (A: Apr. 2022 )(A: Apr. 2023 )
=0.56/( (174.526+189.47 )/ 2 )
=0.56/181.998
=0.31 %

Avid Bioservices's annualized Return-on-Tangible-Equity for the quarter that ended in Oct. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Oct. 2023 )  (Q: Jul. 2023 )(Q: Oct. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Oct. 2023 )  (Q: Jul. 2023 )(Q: Oct. 2023 )
=-38.036/( (190.598+183.675)/ 2 )
=-38.036/187.1365
=-20.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Oct. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Avid Bioservices  (NAS:CDMO) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Avid Bioservices Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Avid Bioservices's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Avid Bioservices (Avid Bioservices) Business Description

Traded in Other Exchanges
Address
14191 Myford Road, Tustin, CA, USA, 92780
Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development and high-quality CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries.
Executives
Matthew R. Kwietniak officer: Chief Commercial Officer 14191 MYFORD ROAD, TUSTIN CA 92780
Richard A. Richieri officer: Chief Operations Officer 14191 MYFORD ROAD, TUSTIN CA 92780
Daniel Ryan Hart officer: Chief Financial Officer 2642 MICHELLE DR., SUITE 200, TUSTIN CA 62780
Mark R Ziebell officer: V.P., General Counsel 14282 FRANKLIN AVENUE, TUSTIN CA 92780
Richard B Hancock director 14282 FRANKLIN AVE., TUSTIN CA 92780
Joseph Carleone director 3883 HOWARD HUGHES PKWY, SUITE 700, LAS VEGAS NV 89169
Nicholas Stewart Green director, officer: President & CEO 2642 MICHELLE DRIVE, SUITE 200, TUSTIN CA 92780
Gregory Sargen director
Esther M. Alegria director 2642 MICHELLE DRIVE, SUITE 200, TUSTIN CA 92780
Mark R Bamforth director 500 KENDALL ST., CAMBRIDGE MA 02142
Jeanne Thoma director C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Patrick D Walsh director 14282 FRANKLIN AVE., TUSTIN CA 92780
Catherine J Mackey director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Joel Mccomb director 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Stephen Michael Hedberg officer: Principal Fin. & Acct. Officer 2642 MICHELLE DRIVE, SUITE 200, TUSTIN CA 92780

Avid Bioservices (Avid Bioservices) Headlines

From GuruFocus

Avid Bioservices Appoints Oksana Lukash as Vice President, People

By Value_Insider Value_Insider 11-16-2022